Belharra Therapeutics

Executive Summary

Belharra Therapeutics is a San Diego-based biotechnology company leveraging its proprietary chemoproteomics platform to discover small-molecule drugs against historically undruggable targets in oncology and immunology. Founded in 2021, the company has raised $50 million in funding to advance its preclinical pipeline. By profiling small-molecule interactions across the entire proteome, Belharra aims to identify novel binding sites and mechanisms, unlocking new therapeutic avenues for cancer and autoimmune diseases. Its platform represents a significant advancement in drug discovery, potentially enabling the targeting of proteins previously considered intractable with conventional methods. Belharra's preclinical stage and focus on high-unmet-need areas position it for potential future milestones, including lead optimization candidate nomination, IND-enabling studies, and strategic partnerships. The company operates in a competitive landscape but differentiates through its comprehensive chemoproteomic approach. Key near-term catalysts include the announcement of a lead program advancement, potential Series B funding to accelerate pipeline development, and validation through collaborations or licensing deals. However, as a preclinical company with no disclosed pipeline specifics, the risk profile is high, and success hinges on platform validation and translation into clinical candidates.

Upcoming Catalysts (preview)

• Q2 2026Lead candidate nomination for oncology program40% success
• Q3 2026Series B funding round65% success
• Q4 2026Partnership or collaboration with a large pharma30% success